AI in Healthcare: Separating Genuine Breakthroughs from the Hype

Healthcare AI has been “on the verge of transformation” for a decade. Some of that promised transformation has arrived; much of it hasn’t. The challenge isn’t capability — it’s deployment, validation, and the particular regulatory and trust requirements of medicine.

Where It’s Actually Working

Medical imaging is the clearest success story. FDA-cleared AI tools for detecting diabetic retinopathy, breast density assessment, pneumonia detection on chest X-rays, and intracranial hemorrhage on CT scans are in clinical use at scale. Outcome data is accumulating and it’s positive.

Drug discovery acceleration is potentially more consequential. AI has substantially compressed the candidate molecule identification phase. AlphaFold’s protein structure predictions have become infrastructure for the pharmaceutical industry.

Clinical documentation via AI scribes (Nuance DAX, Suki, Nabla) has seen strong adoption among physicians motivated to reclaim time from documentation burden.

Where It’s Struggling

Clinical decision support — AI that advises on diagnosis or treatment — faces deep validation challenges. Regulatory pathways are unclear for continuously-updating models. Physician trust is low after years of rule-based “alert fatigue.”

Health equity is an underappreciated problem. Models trained predominantly on data from large academic medical centers perform poorly on underrepresented populations.

The path forward requires more clinical validation data, clearer regulatory guidance, and healthcare organizations treating AI deployment as a clinical governance issue, not just an IT procurement one.